| Today’s Big NewsAug 16, 2023 |
| By James Waldron The path to potential approval for bluebird bio’s lovo-cel has become slightly smoother after the FDA confirmed it will not be holding an advisory committee meeting before making a decision on the sickle cell disease gene therapy in December. |
|
|
|
| Philadelphia, PA |  |
|
|
By Nick Paul Taylor Precision BioSciences has moved quickly to partner its CAR-T cell therapy candidate. Nineteen days after confirming it planned to partner the program, the biotech has agreed to offload the asset to Imugene for $21 million upfront and much more on the back end. |
By Max Bayer Cruising on the midstage clinical success of a brain cancer therapy, Day One Biopharmaceuticals is using the wind at its sails to bolster the back of its pipeline with a $3 million upfront deal for Sprint Bioscience's preclinical program. |
By Nick Paul Taylor Impel Pharmaceuticals’ money miseries have left it looking to lenders for leniency. In breach of a credit agreement, the developer of intranasal drugs has warned it may have to sell assets or file for bankruptcy if it is unable to restructure its deal and secure fresh funding. |
By Fraiser Kansteiner Earlier this week, a securities filing showed Biogen beat out another Big Pharma rival in its quest to obtain Texas-based rare disease outfit Reata. That company’s identity has been revealed as Sanofi, Bloomberg reports, citing people close to the matter. |
By Andrea Park It’s not often that a sequel is better than the original, but one startup developing a new approach to period products is banking on it. |
By Nick Paul Taylor AstraZeneca’s promotion of Breztri Aerosphere has landed it in hot water with the FDA. The agency says an AstraZeneca sales aid made “misleading” claims about the effect of the inhaler on all-cause mortality, prompting it to send a warning letter to CEO Pascal Soriot. |
By Fraiser Kansteiner Concern over the cost of prescription drugs is becoming less of a policy issue and more of a “core value” for voters across party lines, a pollster found. Two pollsters presented results from their recent survey on Tuesday. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we take a closer look at the challenges with new email policies, and the importance of diverse investors and founders. |
|
|---|
|
|
|
October 16-17 | Boston, MA Examine the ways the IRA has impacted the drug pricing and access landscape and review business implications for affordability and evaluate strategies for engaging with stakeholders. Secure your spot today and save $400 on registration. Savings end August 21st! 
|
|
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
